The role of compliance in pharmaceutical cross-border trade is discussed. Compliance involves ensuring goods entering a country conform to all laws and regulations, and is a focus for regulators like NAFDAC in Nigeria and customs services. NAFDAC's role includes inspecting and certifying imported and exported pharmaceuticals to control quality and prevent non-compliant trade. Harmonization of regulatory standards across countries can help increase legitimate cross-border pharmaceutical trade in Africa by improving efficiency and reducing costs.
NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES ACT (NDPS), 1985 WITH RULE Sagar Savale
The Central Acts like Opium Act, 1857,the Opium Act ,1878 and the Dangerous Drugs Act,1930 were enacted a long time ago. With the changing circumstances and the developments in the field illicit drug traffic and drug abuse at national and international level ,many drawbacks have come to notice in the said Acts.
The Government of India has repealed these old Acts and passed “The Narcotic Drugs and Psychotropic Substances Act,1985’’.
These Acts established in 14 November 1985.
An Act to consolidate and amend the law relating to narcotic drugs, to make stringent provisions for thecontrol and regulation of operations relating to narcotic drugs and psychotropic substances 1[, to provide forthe forfeiture of property derived from, or used in, illicit traffic in narcotic drugs and psychotropic substances, toimplement the provisions of the International Convention on Narcotic Drugs and Psychotropic Substances]and for matters connected therewith.
HAQ: Center for Child Rights
B1/2, Ground Floor,
Malviya Nagar
New Delhi - 110017
Tel: +91-26677412,26673599
Fax: +91-26674688
Website: www.haqcrc.org
FaceBook Page: https://www.facebook.com/HaqCentreForChildRights
Narcotic drugs and psychotropic substance act 1985gururaj lulkarni
This act is called ndps act 1985 and this useful. this is the first presentation for understanding the basics of the act. in presentation 2, 3, 4, 5 are giving full information about this act.
this presentation deals with drug price control in India. it has also updated information on drug price regulation. any suggestion regarding this topic is most welcomed.
NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES ACT (NDPS), 1985 WITH RULE Sagar Savale
The Central Acts like Opium Act, 1857,the Opium Act ,1878 and the Dangerous Drugs Act,1930 were enacted a long time ago. With the changing circumstances and the developments in the field illicit drug traffic and drug abuse at national and international level ,many drawbacks have come to notice in the said Acts.
The Government of India has repealed these old Acts and passed “The Narcotic Drugs and Psychotropic Substances Act,1985’’.
These Acts established in 14 November 1985.
An Act to consolidate and amend the law relating to narcotic drugs, to make stringent provisions for thecontrol and regulation of operations relating to narcotic drugs and psychotropic substances 1[, to provide forthe forfeiture of property derived from, or used in, illicit traffic in narcotic drugs and psychotropic substances, toimplement the provisions of the International Convention on Narcotic Drugs and Psychotropic Substances]and for matters connected therewith.
HAQ: Center for Child Rights
B1/2, Ground Floor,
Malviya Nagar
New Delhi - 110017
Tel: +91-26677412,26673599
Fax: +91-26674688
Website: www.haqcrc.org
FaceBook Page: https://www.facebook.com/HaqCentreForChildRights
Narcotic drugs and psychotropic substance act 1985gururaj lulkarni
This act is called ndps act 1985 and this useful. this is the first presentation for understanding the basics of the act. in presentation 2, 3, 4, 5 are giving full information about this act.
this presentation deals with drug price control in India. it has also updated information on drug price regulation. any suggestion regarding this topic is most welcomed.
Introduction , drug regulation system in India, ministry of chemical and fertilizer, national pharmaceutical pricing authority , organization , function of NPPA, procedure of price fixation, procedure of pricing of formulation, comparison between old and latest system of DPCO , drug pricing mechanism, India - the critical analysis of new drug policy
Thank you..
Narcotic drugs and psychotropic substances act, 1985Ravish Yadav
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
National pharmaceutical pricing authority with drugs price control order (dpc...Tushar Morankar
The government has notified the DPCO 2013 under the Essential Commodities Act, 1955, which will give power to the NPPA (National Pharmaceutical Pricing Authority (NPPA )to regulate prices of 348 essential drugs along with their specified
strengths and dosages under NLEM 2011.
Main Features of the DPCO 2013
• The new order will bring 348 drugs & their 652 formulations under price control.
• The new policy uses a market-based pricing mechanism against the earlier proposed cost-plus method. The ceiling price would be calculated by taking the simple average of prices of all brands of a drug with a market share of 1% or more.
All matters relating to NPPA including its functions of price control and monitoring.
Responsible for development of infrastructure, manpower and skills for the pharmaceutical sector.
Work for the promotion and coordination of basic, applied and other research in areas related to the pharmaceutical sector and for international co-operation in pharmaceutical research.
This presentation is related to the drug price control order in India. It will give an idea to the readers how the prices have been fixed for the formulations. How the price has been calculated for scheduled formulations.
Contents :
Introduction
Definitions
Authorities and Officers
The Consultative Committee Prohibition, control and Regulation
Power of Central Govt. to Permit, Control and Regulate
Power of State Govt. to Permit, Control and Regulate
Offences and Penalties
National Fund.
Act related to narcotic and psychotropic substance and illegal drug trafficing in India. In this slide we will disscussed on a very importnent topic Act related to narcotic and pschotropic substances and Illegal drug trafficing. Now a days prevalence of substance or drug abused disorder is increasiing due to illegal drug traffing not only in Inida but all over the world so every counries has made some some act related to these problems.
this presentation explains about tne history, scope, narcotic drugs and psychotropic substances definitions, offences and penalties, controlled operations, amendments, manufactured drugs, favourable conditions, production, sale of opium.
Pharmaceuticals and the WTO TRIPS Agreementjboscariol
A presentation on the application of the obligations and remedies under the WTO\'s agreement on trade-related aspects of intellectual property rights to pharma products. Includes a focus on access to patented medicines for developing countries.
Introduction , drug regulation system in India, ministry of chemical and fertilizer, national pharmaceutical pricing authority , organization , function of NPPA, procedure of price fixation, procedure of pricing of formulation, comparison between old and latest system of DPCO , drug pricing mechanism, India - the critical analysis of new drug policy
Thank you..
Narcotic drugs and psychotropic substances act, 1985Ravish Yadav
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
National pharmaceutical pricing authority with drugs price control order (dpc...Tushar Morankar
The government has notified the DPCO 2013 under the Essential Commodities Act, 1955, which will give power to the NPPA (National Pharmaceutical Pricing Authority (NPPA )to regulate prices of 348 essential drugs along with their specified
strengths and dosages under NLEM 2011.
Main Features of the DPCO 2013
• The new order will bring 348 drugs & their 652 formulations under price control.
• The new policy uses a market-based pricing mechanism against the earlier proposed cost-plus method. The ceiling price would be calculated by taking the simple average of prices of all brands of a drug with a market share of 1% or more.
All matters relating to NPPA including its functions of price control and monitoring.
Responsible for development of infrastructure, manpower and skills for the pharmaceutical sector.
Work for the promotion and coordination of basic, applied and other research in areas related to the pharmaceutical sector and for international co-operation in pharmaceutical research.
This presentation is related to the drug price control order in India. It will give an idea to the readers how the prices have been fixed for the formulations. How the price has been calculated for scheduled formulations.
Contents :
Introduction
Definitions
Authorities and Officers
The Consultative Committee Prohibition, control and Regulation
Power of Central Govt. to Permit, Control and Regulate
Power of State Govt. to Permit, Control and Regulate
Offences and Penalties
National Fund.
Act related to narcotic and psychotropic substance and illegal drug trafficing in India. In this slide we will disscussed on a very importnent topic Act related to narcotic and pschotropic substances and Illegal drug trafficing. Now a days prevalence of substance or drug abused disorder is increasiing due to illegal drug traffing not only in Inida but all over the world so every counries has made some some act related to these problems.
this presentation explains about tne history, scope, narcotic drugs and psychotropic substances definitions, offences and penalties, controlled operations, amendments, manufactured drugs, favourable conditions, production, sale of opium.
Pharmaceuticals and the WTO TRIPS Agreementjboscariol
A presentation on the application of the obligations and remedies under the WTO\'s agreement on trade-related aspects of intellectual property rights to pharma products. Includes a focus on access to patented medicines for developing countries.
Dr. amit gangwal ka pharmaceutical patent presentation
highly exhaustive and updated ppt on pharmaceutical patents, a must watch by all those concerned with the same.
Presented at Michigan State University's WorldTAP International Short Course in Food Safety on July 31, 2009. (http://foodsafetyknowledgenetwork.org/worldtap/foodsafety09)
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
this ppt is about all the rules and regulations of drugs in Japan.this ppt contains the PMDA structure, DMF data, IND and NDA procedure, cosmetic regulations, post marketing survelliance etc.
Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy and banking.
Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy and banking.
History of regulatory affair. Various Regulatory Authority. Role of Regulatory Affairs Department.
Pre-clinical or Non- clinical phase of drug development . Investigational New Drug Application (IND) Importance of IND. Investigator’s Brochure (IB). The Investigator’s Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects. A complete and thorough investigator’s brochure should include the following: Title Page
I. A] Confidentiality Statement
II. Contents of the Investigator’s Brochure
II. A] Table of Contents
II. B] Summary
II. C] Introduction
II. D] Physical, Chemical, and Pharmaceutical Properties and
Formulation
II. E] Nonclinical Studies
II. F] Effects in Humans
II. G] Summary of Data and Guidance for the Investigator. Contents of the Investigator’s Brochure: II. A] Table of Contents
II. B] Summary:
Not longer than 2 pages.
Highlighting significant physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, metabolic and clinical information available that is relevant to the state of clinical development of the investigational product. II. D] Physical, Chemical, and Pharmaceutical Properties
and Formulation:
A description of the investigational product substances including the chemical and or structural formulae and the brief summary of the relevant physical, chemical and pharmaceutical properties.
For safety measures, a description of the formulations to be used including excipients (a substance formulated with the active ingredient of a medication) should be provided and justified if clinically relevant.
Instructions for the storage and handling of the dosage should be provided.
Structural similarities to other known compounds should be mentioned. Pharmacokinetics and Product Metabolism in Humans
A summary of information on the pharmacokinetics of the investigational product(s) should be presented, including the following, if available:
Pharmacokinetics (including metabolism, as appropriate, and absorption, plasma protein binding, distribution and elimination).
Bioavailability of the investigational product (absolute, where possible, and/or relative) using a reference dosage form.
Population subgroups (e.g. gender, age, and impaired organ function).
Interactions (e.g. product-product interactions and effects of food).
Other pharmacokinetic data (e.g. results of population studies performed within clinical trial(s). . Marketing Experience
The Investigator’s Brochure should identify countries where the investigational product has been approved.
The National Policy on Narcotic Drugs and Psychotropic Substances is based on the Directive Principles, contained in Article 47 of the Indian Constitution, which direct the State to endeavor to bring about prohibition of the consumption, except for medicinal purposes, of intoxicating drugs injurious to health.
· Read the overview for Module 4· From the textbook, Internation.docxLynellBull52
· Read the overview for Module 4
· From the textbook, International business law and its environment, read the following chapters:
· National Lawmaking Powers and the Regulation of U.S. Trade
· GATT Law and the World Trade Organization: Basic Principles
· Law Governing Access to Foreign Markets
· From the Argosy University online library resources, read:
· Desai, M., Foley, C., & Hines Jr., J. (2004, December). Foreign direct investment in a world of multiple taxes.Journal of Public Economics, 88(12), 2727–2744. (LIRN Article A152498641)
· Gunter, H. (2006). Global expansion plans broaden horizons. Hotel & Motel Management, 221(18), 1–49. Retrieved from EBSCO database http://search.ebscohost.com/ login.aspx?direct=true&db=buh&AN=22746846&site=ehost-live
· International growth. (2009). Franchising World, 41(2), 93. Retrieved from EBSCO databasehttp://libproxy.edmc.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=bsh&AN=36530783&site=ehost-live
Growth in International Markets
Can managers afford to be conservative when taking decisions related to potential growth prospects?
After a company has successfully entered a foreign market, it may decide to continue to grow. Decisions to invest further can become easier to make based on the company’s experience in that market.
In early 2009, the Hongkong and Shanghai Banking Corporation (HSBC), Europe’s largest bank, announced that it was retreating from its expansion plans in the U.S. HSBC had recorded a $16 billion bad-debt loss in 2008. The loss was from an acquisition that initially cost the bank $14.8 billion. HSBC also had an additional $10 billion write-down on goodwill from its acquisition. The decision was primarily influenced by the eroding U.S. real estate market and a decline in the lending portfolio value of Household Financial, a six-year-old acquisition. Federal policies and regulations such as reduced interest rates, increased money supply, and Troubled Assets Relief Program (TARP) funds were contributing factors.
Raising capital, finding labor, and leveraging existing distribution channels all play a part in the decision to grow further. However, growth in international markets continues to be a challenge despite any circumstances.
Module 4 Overview (2 of 2)
Growth in International Markets
This module will cover the risks associated with growth in international markets.
You will compare the risks of further expansion in an existing market with the risks of expanding into a new market. In your assignment, you will also investigate economic incentives offered to companies that plan on investing. You will also look at the various regulatory issues companies need to take into account prior to further expansion.
CHAPTER 10: Laws Governing Access to Foreign Markets
Left to their own devices, the natural inclination of most nations is to protect their domestic industrial and agricultural base from foreign competition. National governments are easily tempted by t.
A Presentation made to the Governing Council of the Pharmaceutical Society of Nigeria on the occasion of their Inaugural Council Meeting/Retreat. February 27, 2013.
Ethics and Integrity in Service-A Presentation made to the Abia State Executi...Remi ADESEUN
Ethics and Integrity in Service-A Presentation made to the Abia State Executive Council at a Leadership Programme under the auspices of Alpha Institute for Research in Science, Economics and Development. Other Speakers at the Programme were: Prof. Anya O. Anya, Richard Dowden, Bishop Mathew Kukah, Dr Lucy Newman, Dr Chikwe Ihekweazu, Dr Ike Anya.
Participants at the Programme included Prof. Mkpa A. Mkpa (SSG), Mazi Donatus Okorie (Chief of Staff), The Head of Service and all the Honourable Commissioners of the 23 Ministries.
Remi Adeseun Presentation on Nigerian Pharma Industry Code of Promotional Pra...Remi ADESEUN
Nigerian Pharmaceutical Industry (NIPHARMA) Code of Promotional Practices presented by Remi ADESEUN at NIROPHARM Business Networking Dinner held at Lagos Sheraton Hotel on Tuesday Nov 17, 2009.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
2. Introduction
Key Concepts: Globalisation, Global Trade/Cross-Border
(Pharmaceutical)Trade
Focus on Africa
Compliance
Trade (General)
Pharmaceutical
Regulators
NAFDAC
Nigeria Customs Service
Industry (Consumer) Angle
Best Practice
Summary
Remi ADESEUN
3. What is Globalisation?
From the Business Perspective:
Globalisation is the worldwide movement
toward Economic, financial, Trade, and
communications integration.
4 Basic Aspects according to IMF:
trade and transactions,
capital and investment movements,
migration and movement of people
the dissemination of knowledge.[7]
Ref:International Monetary Fund . (2000). "Globalization:
Threats or Opportunity." 12th April 2000: IMF Publications.
4. Globalisation: Context & Focus
Focus of this Paper:
Global Economic
Integration or
Economic
Globalization
process by which an
increasing share of
the economic activity
in the world is taking
place between
people from
different countries
5. What is Global Trade?
The worldwide business that
involves:
making and collecting payments
for transactions in goods and
services,
and transporting them to
interested markets.
Remi ADESEUN
7. What is Cross-Border Trade?
The buying and selling of goods and
services
between businesses in
neighboring countries,
with the seller being in one country and
the buyer in the other country, for
example, a company in the United
States selling to a company in Canada.
Or a company in Nigeria selling to a
company in Ghana.
8. Cross-Border Trade in Africa
“One of the biggest obstacles to
industrialization in Africa is
that African countries trade very little
between themselves,
only 10-12 percent of total trade,
whereas regional trade accounts for
63% in EU, 40% in the US and 30%
in Asean countries.”
Ref: http://kariobangi.com/2012/02/13/are-african-economies-too-
similar/
9. Cross-Border Trade Environment
For Pharmaceuticals
Key Requirements for Understanding
Extensive knowledge of Trade & Customs
Practices around the world
Deep understanding of
import and export laws and regulations,
The Global Supply Chain
Trade Processes and Controls
Extensive knowledge of Pharmaceutical
Laws and Regulations
Forward-thinking attitude/Global Mindset
Harmonisation of Regulatory Requirements
10. Cross-Border Pharmaceutical
Trade in Africa
Harmonisation of Regulatory
Requirements is a key driver for
increased intra-regional trade
East Africa has made significant
progress in this regard by making
Product Registration in one Country
acceptable for trade in another country
Leading to improved Compliance and
enhanced Cross-Border Pharmaceutical
Trade
11. Key Considerations for Successful
Regional Harmonisation in Africa
A need to adopt a step-wise approach to harmonisation (e.g Start
with Generics)
A need to invest in regulatory and industry capacity building,
Acknowledgment that NMRAs must follow through on their mandate
to promote and protect public health
Sustainability, transparency and trust building
Use of existing structures and broader REC strategies to advocate
for AMRH
National sovereignty must be respected,
Existing forums should be used to provide regulators with practical
advocacy (African Medicines Regulators Conference (AFDRAC),
International Conference for Drug Regulatory Authorities (ICDRA),
International Conference on Harmonisation Global Cooperation Group (ICH-
GCG)
Need for the Consortium to keep all stakeholders informed and
involved
Need to capitalise on strategic niche roles of key players
including:WHO, NEPAD, DFID, etc.
12. Industry’s Goals
Improve Efficiency
Harmonisation of Regulatory
Requirements
Speedier Port Clearance
Reduce Cost
Mitigate Risk Issues concerning
conducting cross-border business
13. What is Trade Compliance
Trade compliance is the process by
which goods enter into a Country in
conformance with all laws and
regulations of that Country.
It should be the goal of the Customs
Service to maximize trade compliance
while facilitating the importation of
legitimate cargo.
14. Drivers of Increased Compliance
Focus in Cross-Border
Pharmaceutical Trade
tremendous increase in international
trade and transport,
the growing awareness of trans-
national organized crime and, more
recently,
the threat of terrorism.
increased awareness in Customs
administrations that national and and
international co-operation is essential
15. Pharmaceutical Regulatory Aspects
of Compliance in Cross-Border
Pharmaceutical Trade
Pharmacy & Drug Laws
NAFDAC Act, Cap N1 LFN 2004 (formerly Decree 15 of 1993 as
amended) + 14 Subsidiary Regulations
Drugs and Related Products (Registration, etc) Act Cap F33 LFN 2004
(Formerly Decree 19 of 1993 (as amended)
Pharmacists Council of Nigeria (PCN) Act 91 of 1992
Food and Drugs Act Cap 150 LFN (as amended)
National Drug Formulary and Essential Drugs List Act Cap 252 LFN
1990
Counterfeit and Fake Drugs and Unwholesome Processed Foods
(Miscellaneous Provisions) Cap 34 LFN 2004 (formerly Decree 25 of
1999)
Poisons and Pharmacy Act (PPA) Cap 535 LFN 1990
Dangerous Drugs Act (DDA) Cap 91 LFN 1990
NDLEA Act of 1989
Remi ADESEUN
16. NAFDAC
MANDATE
NAFDAC was established by Decree No. 15 of 1993 (now
NAFDAC Act CAP N1 LFN, 2004) to Regulate and Control the
Importation, Exportation, manufacture, distribution, advertisement,
sale and use of Foods, Drugs, Cosmetics, Medical Devices,
Chemicals, Detergents and packaged water.
This mandate places on Ports Inspection Directorate (PID) the
responsibility of carrying out the following functions and exercising
powers as described in sections 5d,5e and 5g of the NAFDAC Act.
17. NAFDAC Act CAP N1 LFN, 2004
5d) undertake inspection of imported food, drugs, cosmetics, medical devices,
bottled water and chemicals and establish relevant quality assurance
systems, including certification of the production sites and of the
regulated products;
5e) compile standard specifications and guidelines for the production,
importation, exportation, sale and distribution of food, drugs, cosmetics,
medical devices, bottled water and chemicals;
5g) control the exportation and issue quality certification of food, drugs,
cosmetics, medical devices, bottled water and chemicals intended for
export.
NAFDAC
18. NAFDAC controls the importation and exportation of
all the products covered by this Act at the Sea Ports,
Airports and Land borders.
No NAFDAC regulated product shall be imported into
and exported out of Nigeria unless it has been duly
registered and/or issued a permit or certificate in
accordance with the provisions of Act Cap F33 LFN 2004
and the accompanying guidelines.
NAFDAC
19. To control and inspect imported food, drugs, cosmetics, medical
devices, and chemicals at ports of entry.
To control the export of food, drugs, cosmetics, medical devices, and
chemicals and issue quality certification of the above products for
export.
Duties also include compilation of guidelines & regulation for
importation/exportation of regulated products.
Collaborate with other relevant Agencies, Organizations and the
Private Sector at the Ports and Land Borders.
Sampling of relevant products for lab analysis before final release
Implementation of Government fiscal policy on the prohibition of
imports of regulated products through the ports and land borders.
NAFDAC: Functions
20. Imposition of sanctions and administrative penalties for violations
including outright seizures for violative products and apprehension
of culprits.
Operation of 24-hour surveillance at designated airports.
Organizing seminars, workshops and meetings to sensitize, update
and create awareness on NAFDAC regulations as it concerns imports
and exports.
Holding Consultative meetings with sectoral groups and
stakeholders to encourage regulatory compliance.
NAFDAC: Functions
21. A.) IMPORTS:
The divisions in PID ensure proper documentation and
endorsement of customs documents during importation.
The Ports (sea and Air) and Land border offices conduct
physical inspection of goods, Hold assignments, fast track
activities and final release of goods at the various ports and
land borders.
Import Activities occur as:
Pre-clearance Activities
Clearance Activities
Post Clearance Activities
NAFDAC: Operations
22. B.) EXPORTS:
NAFDAC mandate covers the certification of finished pharmaceutical
products that are meant for export.
The following Certificates are issued on satisfying the requirements for
export:
Combined Certificate of manufacture and free sale (for registered
products)
Certificate of Pharmaceutical Products (COPP).
Free sale Certificates for products not manufactured in Nigeria but
sold in Nigeria.
Export Certificate for goods transported through Land Borders for
ECOWAS Market.
NAFDAC: Operations
23. Pre-Clearance Processes involves
Pre-arrival notification.
Clearance Processes involves
E-Clearance Assessment
Payment of NAFDAC Charges
Documentation and First Endorsement
Physical Inspection
Second Endorsement
Release of Goods to importers’ ware
house
NAFDAC: Operations
24. The Federal Government in her wisdom made laws which
empowers several Government Agencies including NAFDAC to
regulate activities at the Ports.
In the light of this, the Federal Government in 2005 adopted the
Destination Inspection (DI) Scheme.
The objectives of the Destination Inspection Scheme include:
1. To improve clearance of goods by using latest technology tools for
documentary checks risk assessment and on the job training.
2. Facilitate trade through Risk Management and the use of non-
intrusive inspection (x-ray scanners) of imports thereby minimizing
the need for physical examination.
3. To enhance Government import revenue collection and the
detection of illegal and false declaration of imports.
Ports Inspection Directorate
NAFDAC: Operations
25. All consignments imported into Nigeria are subjected
to some form of documentary checking and Risk
Assessment. These functions are performed by Nigeria
Customs Service and Webbfontaine Nigeria Limited.
NAFDAC is connected with Nigeria Customs Service on the
Nigeria Trade Hub at www.nigeriatradehub.gov.ng and
http://trade.gov.ng for ports operations.
To facilitate legitimate trade, NCS in collaboration with
regulatory agencies have listed all regulated products into
HS Codes, clearing lanes as follows on the next slide:
NAFDAC: Operations
26. Customs Clearing Lanes
NAFDAC
Customs
Auto release
Output 1
Fast Track
Facility
Output 2
Documentary
Check
Output 3
Scanning
Output 4
Physical
Inspection
Output 5
NAFDAC finished Pharmaceutical products fall under the deep red lane
which is for physical inspection
X
27. ROUTES FOR DRUGS CLEARANCE
NAFDAC.
Drugs,
Food,
Cosmetics
Medical
Devices,
Agrochemicals,
Raw Materials
Lagos Ports
Drugs,
Food,
Cosmetics
Medical
Devices,
Agrochemicals,
Raw Materials
Airports
Food,
Cosmetics,
Agrochemicals
Land Borders
Food, Cosmetics
Medical
Devices,
Agrochemicals,
Raw Materials
Other Sea Ports
Note: Drug products are not allowed through any port except for Lagos Ports and Airports
28. NAFDAC: Procedures for Drugs
Clearance
28 5/29/2014
1. Declaration of
importation on
ASYCUDA at
Customs DTI (Direct
Trader Input) Cafe
2. Costing for NAFDAC
Charges NAFDAC
eClearance Unit
3. First Endorsement
of relevant
documents
4. Physical Inspection of
Products at ports and
importer‘s warehouse
5. Submission of relevant
documents for second
endorsement and release
6. Final
Release
29. NAFDAC: Documents Required for 1st
Stamp for Finished Pharmaceutical
Products
Letter of undertaking &
Introduction (Original Copy)
Certificate of Analysis (Original
Copy)
NAFDAC Certificate of
Registration or Notification
preferably 2013 – 2014
Electronic SGD
CRIA (Original) e.g
*India – QCS, Silis Labs, ACS
*China – NHU, Hanlin Shangai,
Quangzhou Test Tech.
*Egypt - ITG
Photocopy of Payment Advice
Form C-30
Annual License to practice as a
Pharmacist
Retention of Premises
NAFDAC receipt of payment
Permit to Import & Permit to Clear
Controlled Substances
Packing list
Bill of lading/Airway bill
Invoice
Pre-Shipment Information for
Finished Pharmaceutical Products
Form M
5/29/2014 29
30. NAFDAC: Documents Required for 2nd
Stamp for Finished Pharmaceutical Products
& Controlled Substances
Certificate of Analysis/CRIA
Invoice
Electronic SGD
Bill of Lading/Airway Bill
Form M
Packing List
PAAR (Pre-Arrival Assessment Report)
Physical Examination Sheet
NAFDAC Reg. Certificate
Permit to Import & Permit to Clear (Original where
applicable)
5/29/2014 30
31. 5/29/2014 31
Documents not originating from NAFDAC and
used by Nigeria Customs Service for the
clearance of NAFDAC regulated products
S/NO DESCRIPTION
1 Single Goods Declaration
2 Pre Arrival Assessment Report
3 Form M
4 Bill of Lading/Airway Bill
5 Packing List
6 Invoice
Documents not originating from
NAFDAC and used exclusively by
NAFDAC for the clearance of NAFDAC
regulated products
S/NO DESCRIPTION
1
Certificate of Analysis of the
product
2
Pharmacist License and
Premises Licence
3
Clean Report of Inspection &
Analysis (CRIA)
NAFDAC: Operations
32. 5/29/2014 32
Documents originating from NAFDAC and used for the clearance of
NAFDAC regulated products
S/NO DESCRIPTION
1
NARCOTICS AND CONTROLLED SUBSTANCES
DIRECTORATE (NCS)
Permit to import Narcotics substances
Permit to import Psychotropic and Other controlled
Substances
2
CHEMICAL EVALUATION AND RESEARCH DIRECTORATE
(CER)
Permit to import Controlled Chemicals and Solvents
3
REGISTRATION AND REGULATORY AFFAIRS
DIRECTORATE (R&R)
Certificate of Registration/Notification of Registration
Preferably 2013 - 2014
NAFDAC: Operations
33. Functions of Nigeria Customs
Service in the Nigerian Economy:
i. Revenue Collection
Customs & Excise Management Act, Cap 84 Laws of the
Federation [CEMA, Section 4], LFN.1990 – power to
control and manage administration of the Customs &
Excise Laws. Collects and account for revenue.
[ii] Anti – smuggling operations
Applicable at: Borders, sea and airports – checks
contrabands, hazardous goods, national security
interest.
Physical interception, examination of goods and
documents.
33
34. Functions of Nigeria Customs
Service in the Nigerian Economy:
Agency Function (Inter-Agency)
NCS performs inter-agency functions on behalf of other
government agencies, namely;
Nigeria Police Force – seizure of arms and ammunitions.
National Agency for Food and Drug Administration and Control
[NAFDAC] – prevents illegal importation of foods, drugs and
chemicals.
National Drug Law Enforcement Agency [NDLEA] – prevents
importation and exportation of hard drugs.
34
35. Nigeria Customs Service (NCS):Trade
Facilitation Objectives
Generation of Trade Statistics
Trade Facilitation
Trade facilitation at the core of Customs operations
due to the following
Developments in the WTO with emphasis on trade
liberalization and facilitation.
Development of Free Trade Areas across the regions
of the world – removing tariff and non-tariff barriers
to speed up economic development .
NCS strategic positions at the entry and exit points of
Nigerian borders; lead agency role
35
36. Nigeria Customs Service (NCS):
Trade Facilitation Objectives
To improve the trade environment and
reduce transactions cost between
business and government.
To attract Foreign Direct Investment
(FDI).
To make Nigeria’s borders competitive
by un-impeded flow of goods, services
and investment funds through the
borders.
36
37. I. Implementation of global best practices as a core objective
of NCS modernization agenda.
II. Revised Kyoto Convention (RKC) on the simplification
and harmonization of Customs procedures- Pre-
lodgement and Pre-registration.
III. WCO guidelines on immediate release of consignment -
PreArrival processing.
IV. Facilitation of trade through provision of adequate &
accurate information in the Nigeria Trade Hub Portal (NTH).
NCS New PAAR Policy
38. What is PAAR?
•P- Pre
•A- Arrival
•A- Assessment
•R- Report
•Pre-Arrival Assessment Regime allows importer/Agents to
submit import Documents for assessment and issuance of
PAAR (for Clearance) before the arrival of the cargo
39. PAAR Application provides timely multi-dimensional risk analysis at every
stage of Customs processes.
40. Risk Management Approach in
Customs Controls
Risk: The potential for non-compliance
with Customs (& NAFDAC) laws.
Risk analysis: Systematic use of
available information to determine how
often defined risks may occur and the
magnitude of their likely consequences.
Risk areas: Those Customs procedures
and categories of international traffic
which present a risk.
41. Risk Management Approach in
Customs Controls...2
Risk assessment: The systematic
determination of risk management priorities
by evaluating and comparing the level of
risk against predetermined standards,
target risk levels or other criteria.
Risk indicators: Specific criteria which,
when taken together, serve as a practical
tool to select and target movements for
their potential for non-compliance with
Customs law.
42. Risk Management Approach in
Customs Controls...3
Risk management: Logical and
systematic method of identifying,
analyzing and managing risks. Risk
management can be associated with
any activity, function or process
within the organization and will
enable the organization to take
advantage of opportunities and
minimize potential losses.
43. Risk Management Approach in
Customs Controls...4
Risk profile: A predetermined,
comprehensive and relevant
combination of characteristics or risk
indicators, based on information
which has been gathered, analyzed
and categorized.
44. Risk Management Approach in
Customs Controls...5
Risk profiling: The means by which Customs
put risk management into practice. It replaces
random examination of documents and goods
with planned and targeted working methods
that use profiles as a basis.
Standardized Risk Assessments
(SRAs): These Assessments produce risk
indicator products for use by Customs officials
for the purpose of targeting goods and
conveyances in their daily work.
45. Consumer Protection
Service Failure
Arising from Agencies and Service
Providers
Remedy
Waive Penalties for Infractions that are
beyond the control of Companies
Dispute Resolution Mechanism
No Agency must be allowed to be
Prosecutor, Judge and Jury
46. Best Practice:
Customs Trade Compliance
Focused Assessments (FA)
a detailed review of the company's internal controls for
Customs transactions coupled with an audit of selected import
transactions.
Goal: determine the company's current level of compliance,
and whether or not there are sufficient systems in place to
ensure a high level of compliance with Customs laws and
regulations for future transactions.
Outcome: Compliant or Non-Compliant.
If Non-Compliant, the company will be required to formulate
a compliance improvement plan (CIP), and tender any
revenue found to be owing.
48. Summary
Globalisation:
Has led to greatly increased volume of Global and Cross-Border
Trade
Increased fortunes for developed nations and increased
opportunities for smart developing nations
Developing nations need to take advantage of Globalisation for
prosperity while avoiding inequalities of wealth distribution
All need to be aware of the risks that have come with Globalisation
and mitigate against them
Cross-Border Trade:
Essentialy between Neighbours
Regional Cooperation is enlightened self-interest and should be
encouraged
Inventory the relevant National laws/regulations and harmonise
across the region
Keep all stakeholders actively informed and involved
49. Summary
Trade Compliance:
Conventionally driven by Customs
Customs should regularly compile and communicate Compliance
Issues/Breaches to Industry with a view to aiding improvement
Goal should be facilitation of Trade not encumbrance
Policy implementation must be customer-centric and culture must
be to protect consumer rights while pursuing National Interest
Dispute Resolution Systems and Structure must be established
Cross-Border Pharmaceutical Trade (CBPT):
Deference should be given to the difference between Professionally
Regulated Pharmaceutical Trade and Trade in General Goods
There should be greater inter-agency collaboration especially
between Customs and NAFDAC given the key role the latter plays
in regulating CBPT
Companies need to establish Compliance Management Desks and
give it appropriate Executive Oversight
50. Thank You!
Contact Information:
Remi ADESEUN
Chairman
Programs Committee
Pharmaceutical Society of Nigeria
08057713769/07065156473
radeseun@gmail.com
r.adeseun@rodot.org